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Abstract 
Background: The numerous drawbacks of current serological tests for diagnosis of brucellosis which mainly results 
from cross reactivity with LPS from other gram‑negative bacteria have generated an increasing interest to find more 
specific non‑LPS antigens. Previous studies had indicated that Brucella VirB12 protein, a cell surface protein and com‑
ponent of type IV secretion system, induces antibody response during animal infection. However, this protein has not 
yet been tested as a serological diagnostic marker in human brucellosis.
Methods: Recombinant VirB12 protein was prepared and evaluated the efficacy of it in an indirect enzyme‑linked 
immunosorbent assay (ELISA) for brucellosis with sera collected from different region of Iran and the results were 
compared with a commercial ELISA kit.
Results: Sera from human brucellosis patients strongly reacted to the purified recombinant VirB12. The sensitiv‑
ity, specificity, accuracy, negative predictive value and positive predictive value of recombinant VirB12‑based ELISA 
related to the commercial‑ELISA method were 87.8, 94, 90, 80 and 96.6% respectively.
Conclusions: We concluded that antigenic VirB12 have a property value that can be considered as a candidate for 
using in serodiagnostic tests for human brucellosis.
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Background
Brucella spp. is a facultative intracellular pathogen that 
can be involved with many tissues and organs leading to a 
chronic infection, Brucellosis, in animals and humans [1–
5]. Brucellosis is caused by several species of the genus 
Brucella including Brucella abortus, Brucella meliten-
sis, Brucella suis, Brucella canis, Brucella ovis, and Bru-
cella neotomae [6–9]. B. melitensis is the most frequently 
isolated species which is endemic in many developing 
countries [10, 11]. Clinical manifestations of brucello-
sis are very similar to other febrile diseases; therefore, 
the clinical diagnosis of this disease remains a challenge 
[12]. Common laboratory tests include either bacterio-
logical culture of the pathogen or serological titration 
of anti-Brucella antibody. Although the gold standard 
test is said to be bacteriological isolation, the success 
rate of blood cultures is around 70–80% of cases in acute 
disease produced by B. melitensis [13]. This rate is very 
much lower in chronic cases. Various factors including 
disease duration, isolation method, and prior antibiotic 
intake can drastically impact the bacteriological diagno-
sis [2]. Serum agglutination serological tests often rely on 
detection of antibody against smooth lipoplysaccharide 
(LPS) present on bacterial cell surface. Due to existence 
of extensive cross reactivity with LPS from other gram 
negative bacteria, the specificity of these approaches are 
poorly suited for use in general diagnostic laboratories [2, 
14–18]. The drawbacks of these classical serological tests 
have generated an increasing interest in finding more 
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specific non-LPS based antigen candids [2, 19, 20]. In this 
regard, the outer membrane proteins of Brucella species 
have been proposed as appropriate candidate for anti-
genic component. Rolan et  al. [21] noted that Brucella 
VirB12 protein, a component of type IV secretion system, 
which is situated on bacterial cell surface, is expressed 
during infection and induces an antibody response in 
cattle. However, they had not looked at any possible 
humoral response in humans during active or chronic 
infections. In a previous communicate we reported clon-
ing of the virB12 gene of B. melitensis [22]. In the present 
study, we are reporting expression and purification of the 
recombinant VirB12 protein. Furthermore, the seroreac-
tivity of the purified recombinant virB12 of B. melitensis 
was evaluated with human serum samples in an indi-
rect enzyme-linked immunosorbent assay (ELISA) for 
brucellosis.
Methods
Preparation and recognition of Brucella VirB12 
recombinant protein
The plasmid construct pET28a-VirB12 was purified from 
an overnight culture of Escherichia coli DH5α cell. The 
construct was transformed into competent E. coli Bl21 
(ED3) cells. The cell harboring recombinant plasmid was 
spread on Luria-Bertani (LB) agar culture medium con-
taining kanamycin. After verification, the transformed 
E. coli BL21 cells harboring the PET28a-VirB12 plasmid 
were used in the expression study. A single colony of the 
transformed cell was incubated overnight in 2  ml LB 
broth medium containing kanamycin (100 µl/ml) at 37 °C 
with constant shaking (200 rpm). The next day, 500 µl of 
culture materials was removed and incubated in 200 ml 
LB broth. The culture was grown to an OD600 nm of 0.6 
with vigorous shaking (200 rpm) at 37 °C. Isopropyl-β-d- 
thiogalactopyranoside (IPTG) was added to a final con-
centration of 1 mM for expression of VirB12 recombinant 
protein. The incubated period was continued for another 
4 h at 37 °C with shaking at 200 rpm. For analysis of pro-
duction of the expressed protein, bacterial suspension 
were tested at 2 and 4 h intervals and analyzed on 12% 
SDS-PAGE. Following the fermentation process, cells 
were harvested by centrifugation at 6000×g for 15 min at 
4  °C. Supernatants were discarded and cell pellets were 
frozen at −70  °C. The cell pellets were suspended with 
10 mM Na2HPO4, 10 mM NaH2PO4 and 500 mM NaCl 
(pH, 7.4) and disrupted by sonication for 2  min. After 
sonication, the mixture was centrifuged at 15.200×g for 
15 min at 4 °C. The pellet containing insoluble recombi-
nant VirB12 protein (inclusion bodies) was washed three 
times with 50  mM Tris-Hcl, 10  mM EDTA, 100  mM 
NaCl and 0.5% Triton–X100 (pH 8). The pellet was resus-
pended in buffer containing 8 M urea, 10b mM TrisHcl 
(pH 7.4) and solubilized for 4 h by stirring at room tem-
perature. The solubilized inclusion body was centrifuged 
at 15.200×g for 40 min at 4 °C, and the supernatant was 
collected. Affinity chromatography Ni-NTA column was 
used to purify VirB12. Were loaded onto Ni2—charged 
Hitrap column pre-equilibrated with 8 M urea in 20 mM 
sodium phosphate buffer, pH 7.4. VirB12 was eluted using 
a linear gradient with imidazol (10-500 mM) in 8 M urea, 
pH 7.4. Protein purification was monitored by 280  nm 
absorbance. Recombinant protein was analyzed by 12% 
sodium–dodecyl sulfate polyacrylamide gel electropho-
resis, followed by coomassie Brilliant Blue 250 staining. 
Refolding was performed with cheotropic agent concen-
tration gradient dialysis. The solution of denatured pro-
tein was dialyzed against 2 lit of freshly prepared 6, 4, 2, 
1, 0 M urea with 5 mMTris (pH 7.4). With each concen-
tration, the protein was dialyzed 12  h at 4  °C. Bradford 
method with bovine serum albumin (BSA) as a standard 
was used to assay protein concentration. Purified protein 
was evaluated by western blot using an anti His-tag-HRP 
antibody.
Immunoreactivity of recombinant Brucella purified rVirB12 
to human sera using western blotting
Recombinant protein was subjected to 12% gradient 
SDS-PAGE with the molecular protein marker and was 
transferred from the unstained polyacrylamide gel onto 
0.45  µm nitrocellulose membrane. The blotted mem-
brane blocked using 5% skim milk in TSBST 1%. After 
washing with TSBT, transferred proteins were immu-
nostained with serum obtained from human brucello-
sis infection at a dilution of 1/1000. Secondary antibody 
conjugated to horseradish peroxidase was used in the 
assay. The reaction was visualized with enhanced chemi-
luminescence (ECL) and ECL system (GE Healthcare. 
Uppsala, Sweden).
Production of polyclonal anti‑virB12 recombinant protein 
in rabbit
A mature white New Zealand rabbit was immunized with 
purified VirB12 recombinant protein. Immunization was 
performed according to the protocol of Hay et  al. [23]. 
In the first i.m injection, mixture of 250 µg recombinant 
protein with the same volume of Freund’s complete adju-
vant was injected. For second injection the rabbit was 
injected with 125 µg recombinant protein with the same 
volume of Freund’s incomplete adjuvant, 1, 2 weeks later. 
Finally, 2 weeks after the last immunization, blood was 
collected and sera separated.
ELISA test with commercial kit
To investigate the serological status of the samples from 
human and evaluate the quality of the detection method, 
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all of 100 serum samples were subjected to ELISA kit 
(IBL, Germany). The plate wells of IBL ELISA kit were 
coated with a bacterial lysate of B.abortus strain w99 as 
the antigen. Ref comparsion of four commercial IgM and 
IgG ELISA kits for diagnosing brucellosis.
Immunoreactivity of recombinant Brucella virB12 
to human sera using ELISA
Positive samples were from the patients with a positive 
ELISA test. Clinical sera from human were analyzed by 
indirect ELISA using recombinant VirB12 as antigen. 
The immunoassay plates (Maxisorp, nunc, Denmark) 
were coated with purified recombinant VirB12 pro-
tein at a concentration of 5 µg/ml in PBS and incubated 
at 4  °C, overnight. The wells emptied and washed three 
times with phosphate buffer saline-Tween20 (PBST) and 
then blocked with 5% skim milk for 2 h at 37  °C. Plates 
were filled with sera at a dilution of 1/100 and incubated 
at 37 °C for 1 h. After washing with PBST for five times 
the plates were incubated with HRP conjugates for 1  h 
at 37  °C. After washing with PBST, the wells of plates 
were charged with substrate solution containing TMB 
(3,3′,5,5′-tetra methyl benzidine). Color development was 
stopped by adding H2SO4 20%, after 10 min of incubation 
of the plates in dark at room temperature. Absorbance 
was measured at 450 nm wavelength in an ELISA reader. 
Each samples run in duplicate. Additionally, as a control 
for each serum, wells were left uncoated. To determine 
the cut off value for ELISA 60 known positive and 40 
known negative sera for human brucellosis were used.
Evaluation of ELISA method against commercial ELISA
The sensitivity, specificity, positive predictive value and 
negative predictive value of recombinant VirB12 ELISA 
for serodiagnosis of brucellosis were evaluated in com-
parison to commercial ELISA kit.
Results
Preparation and recognition of Brucella VirB12 
recombinant protein
The pET28a-VirB12 recombinant plasmid was trans-
formed in Bl21 (DE3) E. coli cells. Bacteria harbor-
ing recombinant plasmid were grown in LB medium. 
They were induced with 1  mM IPTG to express target 
recombinant protein. Samples were taken before and at 
1  h intervals after induction. Total protein was electro-
phoresed on 12% SDS PAGE gel. SDS-PAGE analyses 
showed the expected molecular mass of approximately 
25  kDa fusion recombinant protein. The recombinant 
VirB12 was mostly accumulated in the cytoplasm of E. 
coli transformant as inclusion bodies which could only 
by extracted and purified under denaturing condition 
using 8  M urea (Fig.  1). The recombinant VirB12 was 
mostly accumulated in the cytoplasm of E. coli transfor-
mant as inclusion bodies, which could only by extracted 
and purified under denaturing condition using 8  M 
urea. Following purification of rViB12 by Ni-NTA affin-
ity chromatography, the yield of the purified protein was 
estimated by Bradford method to be about 0.6 mg/ml of 
culture (Fig. 2).
Immunoreactivity of recombinant Brucella purified rVirB12 
to human sera using western blotting
To evaluate immune reactivity of the purified protein, 
western blot was performed with sera (1/1000 dilution) 
from Brucella infected human. The sera from human 
reacted to purified recombinant VirB12. Antigenicity 
of the expressed protein was confirmed by western blot 
analysis using patient sera. The specific antibody response 
from five patient sera was observed. Serum samples from 
normal individual was also tested as negative control and 
no anti VirB12 antibodies were detected. Additionally, 
there was no reactivity between the expressed pET28a in 
E. coli Bl21 (DE3) with patient serum (Fig. 3).
Production of polyclonal anti‑virB12 recombinant protein 
in rabbit
Increasing the antibody titers to high level after third 
boost was confirmed the good immunogenicity of 
VirB12. The rabbit antiserum was able to recognize the 
virB12 in Brucella lysate and the purified recombinant 
VirB12.
Fig. 1 Analysis of expressed VirB12 recombinant protein at differ‑
ent times after induction on SDS‑PAGE (12% w/v). Lane 1 protein 
molecular mass marker (KDa). Lane 2 protein expression in Bl21 (DE3) 
with pET28a vector 1 h after adding IPTG. Lane 3 protein expression 
in transformed Bl21 (DE3) with pET28a‑VirB12 recombinant vector 
before adding IPTG. Lane 4 protein expression in transformed Bl21 
(DE3) with pET28a‑VirB12 recombinant vector 1 h after adding IPTG. 
Lane 5 protein expression in transformed Bl21 (DE3) with pET28a‑
VirB12 recombinant vector 2 h after adding IPTG. Lane 6 protein 
expression in transformed Bl21 (DE3) with pET28a‑VirB12 recombi‑
nant vector 4 h after adding IPTG
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Evaluation of recombinant VirB12 ELISA
Immune reactivity of recombinant virB12 was deter-
mined using an indirect ELISA. A total 100 serum 
samples (66 commercial-ELISA positive and 34 com-
mercial-ELISA negative) were collected from different 
region of the country and were tested by indirect ELISA 
against the recombinant VirB12 antigen. The VirB12 
ELISA was considered positive only if the mean absorb-
ance value was greater than two SDS above the mean 
value for healthy serum samples. The cut of value was 
0.325 (mean, 0.17 SD, 0.077). Out of 100 serum samples 
tested, 60 (60%) were positive and 40 (40%) were negative 
by ELISA. The sensitivity, specificity, accuracy, negative 
predictive value and positive predictive value of recom-
binant VirB12-based ELISA related to the commercial-
ELISA method are shown in Table 1.
Discussion
Despite using vaccination in livestocks, brucellosis 
remains as an endemic infection in many developing 
countries such as Iran. Human and animal infection 
with Brucella inflicts an enormous cost to people and 
government [24]. Since culture method for diagnosis of 
Brucellosis is time consuming and has infection risk for 
laboratory workers, serological tests are commonly used 
for clinical diagnosis [25]. Due to cross reactions with 
many other Gram negative bacteria in most routinely 
used LPS-based serological tests, identification of more 
specific Brucella spp. protective antigens can be useful 
for developing serological tests which avoid the draw-
backs of classical ones. The outer membrane proteins in 
Gram negative bacteria have particular significance as a 
potential immunity target [26]. Brucella VirB12 is one of 
Fig. 2 SDS‑PAGE analysis of recombinant VirB12 protein expression 
and its purification. Lane 1 elution of recombinant VirB12 protein 
through Ni‑NTA column. Lane 2 protein molecular mass marker (KDa). 
Lane 3 protein protein expression in transformed Bl21 (DE3) with 
pET28a‑VirB12 recombinant vector 3 h after adding IPTG
Fig. 3 Western blot analysis against recombinant VirB12 protein by 
infect patient sera. Lane 1 western blotting with patient positive Bru‑
cella serum (1/500 diluation). Lane 2, 3 western blotting with patient 
positive Brucella serum (1/100 diluation). Lane 4 western blotting with 
normal individual
Table 1 Evaluation of  diagnostic value of  recombinant 
VirB12 antigen-based ELISA against commercial ELISA
Sensitivity: true positive/true positive + false negative*100 = 87.8%
Specificity: true negative/true negative + false positive*100 = 94%
Positive predictive value: true positive/true positive + false 
positive*100 = 96.6%
Negative predictive value: true negative/true Negative + False 
positive*100 = 80%










Total 66 34 100
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these structural protein which is expressed during Bru-
cellosis infection. Investigators had demonstrated that 
VirB12 protein acts as an immunogen and induces par-
tial immunity in animal models [27]. However, there is 
not any report concerning antigenicity of the recombi-
nant VirB12 protein in human. VirB12 protein is located 
on the bacterial cell surface and is highly conserved 
among Brucella isolates. Therefore, VirB12 can be con-
sidered as an antigenic candidate for serological diag-
nosis of brucellosis. Use of recombinant VirB12 instead 
of extracted VirB12, is less time consuming, has a high 
yield and avoids handling with live pathogenic Brucella. 
In the present study, high level expression of VirB12 pro-
tein was carried out by the means of pET28a based on T7 
promoter transcription translation signals in conjunction 
with suitable host cell E. coli Bl21 (DE3). The results of 
SDS-PAGE demonstrated that an IPTG concentration 
of 1 mM and 4 h of incubation under shaking condition 
was optimum for expression of protein. The cloning of 
VirB12 gene in the pET28 system led to expression of a 
protein with size of approximately 25 kDa. The expressed 
protein contained 6 His Tag which is linked to the C-ter-
minal of protein. These additional amino acids increase 
the size of expressed protein by 8 KDa. The presence of 
His tag sequence in the target protein also provides the 
possibility for purification through Ni-NTA affinity chro-
matography. Metal affinity chromatography was subse-
quently performed to purify VirB12, producing amount 
3  mg of pure recombinant protein per liter of bacterial 
culture. Antigenicity of the purified protein component 
was evaluated in immunoblotting with human brucello-
sis sera. Data showed that the recombinant VirB12 pro-
tein could be detected as an antigenic component by sera 
from acute phase of human brucellosis. By using western 
blot analysis, we showed that the recombinant VirB12 
did not shown any cross reactivity with normal human 
sera. There was also no serological interference related 
to the fused amino acids. The results, in consist of other 
researcher showed that there was no interference related 
to fused amino acids [12]. To examine the practical value 
of VirB12, 100 positive and negative serum samples from 
different part of country used in virB12 antigen based 
indirect ELISA for detection of antibody response against 
Brucella. The finding demonstrated that the virB12 
recombinant protein had good immunogenicity and 
indicates that the availability of virB12 to the immune 
system. The Pearson correlation coefficient of the virB12 
antigen-based indirect ELISA against commercial ELISA, 
a test based on LPS antigen was 0.73 (P < 0.001). The sen-
sitivity of the virB12-ELISA was 87.8% and specificity 
was 94%. The accuracy in all samples reached 90%. The 
sensitivity and specificity of virB12 ELISA in comparison 
with commercial ELISA confirmed the fact this system 
comparable to the commercial assay available as a poten-
tial immunogenic marker for screening of brucellosis and 
needs further evaluation.
Conclusions
In summary, our results showed that VirB12 was expressed 
at high amounts in E. coli Bl21 and could be purified by Ni-
NTA affinity chromatography. This recombinant protein 
reacted strongly with sera from patient with brucellosis by 
western blot. Thus we concluded that VirB12 is antigenic 
and has property to be considered as a suitable candidate 
for development of more specific diagnostic tests.
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